De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients

Hepatology International

Volumn 5, Issue 2, 2011, Pages 671-676

  Wang, Li Chun ^a,b   Chen, En Qiang ^a,b   Cao, Jing ^c   Liu, Li ^a,b   Zheng, Li ^a   Li, Da Jiang ^a   Xu, Lu ^a,b   Lei, Xue Zhong ^a,b   Liu, Cong ^a,b   Tang, Hong ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Combination treatment; Entecavir; HBeAg negative; Lamivudine; Monotherapy

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL;

EID: 79956278410     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9243-x     Document Type: Article

References (22)

1. JJ Feld DK Wong EJ Heathcote 2009 Endpoints of therapy in chronic hepatitis B Hepatology 49 S96 S102 19399800 10.1002/hep.22977 1:CAS:528:DC%2BD1MXlvFKqsL0%3D
2. CK Hui GK Lau 2007 Treatment of hepatitis B e antigen-negative patients Curr Treat Options Gastroenterol 10 474 482 18221608 10.1007/s11938-007-0047-6 (Pubitemid 350284930)
3. D Shouval CL Lai TT Chang, et al. 2009 Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy J Hepatol 50 289 295 19070393 10.1016/j.jhep.2008.10.017 1:CAS:528:DC%2BD1MXntVGhtg%3D%3D
4. WS Ayoub EB Keeffe 2008 Review article: current antiviral therapy of chronic hepatitis B Aliment Pharmacol Ther 28 167 177 18466358 10.1111/j.1365-2036.2008.03731.x 1:CAS:528:DC%2BD1cXps1Gmsb0%3D (Pubitemid 351861968)
5. B Degertekin AS Lok 2009 Update on viral hepatitis: 2008 Curr Opin Gastroenterol 25 180 185 19387254 10.1097/MOG.0b013e328324f478
6. PW Angus SJ Patterson SI Strasser GW McCaughan E Gane 2008 A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis Hepatology 48 1460 1466 18925641 10.1002/hep.22524 1:CAS:528:DC%2BD1cXhsVKmtrfO
7. SJ Patterson PW Angus 2009 Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues Curr Opin Organ Transplant 14 225 230 19373086 10.1097/MOT.0b013e32832b1f32
8. N Akuta F Suzuki Y Kawamura, et al. 2008 Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil Intervirology 51 385 393 19229115 10.1159/000203283 1:CAS:528:DC%2BD1MXktFSru74%3D
9. EQ Chen LC Wang J Lei L Xu H Tang 2009 Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus Virol J 6 163 19818142 10.1186/1743-422X-6-163
10. S Ijaz C Arnold S Dervisevic, et al. 2008 Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy J Med Virol 80 1160 1170 18461609 10.1002/jmv.21206 1:CAS:528:DC%2BD1cXnt12qu7Y%3D (Pubitemid 351705994)
11. E Palumbo 2008 Entecavir for chronic hepatitis B: a review Ther Drug Monit 30 1 4 18223455 10.1097/FTD.0b013e318164f6f1 1:CAS:528: DC%2BD1cXhtVCru7c%3D (Pubitemid 351161091)
12. PN Cheng TT Chang 2008 Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients Expert Rev Anti Infect Ther 6 569 579 18847396 10.1586/14787210.6.5.569 1:CAS:528:DC%2BD1cXht1Glu7vP
13. DJ Tenney RE Rose CJ Baldick, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 1503 1514 19280622 10.1002/hep.22841 1:CAS:528:DC%2BD1MXlslKmurw%3D
14. Y Suzuki F Suzuki Y Kawamura, et al. 2009 Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 24 429 435 19226381 10.1111/j.1440-1746.2008.05760.x 1:CAS:528:DC%2BD1MXltFCgtLg%3D
15. YF Liaw CM Chu 2009 Hepatitis B virus infection Lancet 373 582 592 19217993 10.1016/S0140-6736(09)60207-5 1:CAS:528:DC%2BD1MXhvFGltLk%3D
16. P Lampertico M Colombo 2009 HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues Liver Int 29 Suppl. 1 130 132 19207976 10.1111/j.1478-3231.2008.01931.x
17. GV Papatheodoridis M Deutsch 2008 Resistance issues in treating chronic hepatitis B Future Microbiol 3 525 538 18811237 10.2217/17460913.3.5.525 1:CAS:528:DC%2BD1cXhtFGlu7bP
18. C Fournier F Zoulim 2008 Combination therapy in chronic hepatitis B Gastroenterol Clin Biol 32 S42 S49 18662609 10.1016/S0399-8320(08)73264-0 1:STN:280:DC%2BD1cvosVGrsg%3D%3D
19. M Morgan EB Keeffe 2009 Diagnosis and treatment of chronic hepatitis B: 2009 update Minerva Gastroenterol Dietol 55 5 22 19212304 1:STN:280: DC%2BD1M7js1WrsQ%3D%3D
20. YH Huang JC Wu TT Chang, et al. 2003 Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan J Viral Hepat 10 277 284 12823594 10.1046/j.1365-2893.2003.00428.x (Pubitemid 36801914)
21. SK Fung F Wong M Hussain AS Lok 2004 Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B J Viral Hepat 11 432 438 15357648 10.1111/j.1365-2893.2004.00556.x 1:STN:280:DC%2BD2cvltVOgtA%3D%3D (Pubitemid 39336224)
22. P Marcellin EJ Heathcote M Buti, et al. 2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2442 2455 19052126 10.1056/NEJMoa0802878 1:CAS:528:DC%2BD1cXhsVCrurjL